Dr. Michelotti is a biochemist with special expertise in the analysis of large metabolomics and gene expression datasets. As principle investigator of a translational research laboratory at Duke University for 15 years, Dr. Michelotti successfully attracted both federal and pharmaceutical grants. His laboratory contributed to the identification of novel G protein coupled receptor-mediated stress-response cascades that contribute to de-regulated epithelial growth responses. Collectively, this work resulted in the publication of over 70 peer reviewed publications, resulting in an h-index of 31. Dr. Michelotti joined Metabolon in 2015 to apply his expertise in signal transduction, cancer biology, and metabolism to assist investigators in the successful design and execution, and analysis of large metabolomic data sets to provide biological insight into complex human pathologies.
Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the microbiome field: